These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

724 related articles for article (PubMed ID: 12637461)

  • 101. ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer.
    Stål O; Borg A; Fernö M; Källström AC; Malmström P; Nordenskjöld B;
    Ann Oncol; 2000 Dec; 11(12):1545-50. PubMed ID: 11205461
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer.
    van de Water W; Markopoulos C; van de Velde CJ; Seynaeve C; Hasenburg A; Rea D; Putter H; Nortier JW; de Craen AJ; Hille ET; Bastiaannet E; Hadji P; Westendorp RG; Liefers GJ; Jones SE
    JAMA; 2012 Feb; 307(6):590-7. PubMed ID: 22318280
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis.
    Chen J; Zhang X; Lu Y; Zhang T; Ouyang Z; Sun Q
    Breast Cancer; 2021 May; 28(3):630-643. PubMed ID: 33387283
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer.
    Ingle JN; Green SJ; Ahmann DL; Long HJ; Edmonson JH; Rubin J; Chang MN; Creagan ET
    J Clin Oncol; 1986 Jun; 4(6):958-64. PubMed ID: 3519885
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study.
    Pico C; Martin M; Jara C; Barnadas A; Pelegri A; Balil A; Camps C; Frau A; Rodriguez-Lescure A; Lopez-Vega JM; De La Haba J; Tres A; Alvarez I; Alba E; Arcusa A; Oltra A; Batista N; Checa T; Perez-Carrion R; Curto J;
    Ann Oncol; 2004 Jan; 15(1):79-87. PubMed ID: 14679124
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Prognostic factors in elderly women with metastatic breast cancer treated with tamoxifen: an analysis of patients entered on four prospective clinical trials.
    Dhodapkar MV; Ingle JN; Cha SS; Mailliard JA; Wieand HS
    Cancer; 1996 Feb; 77(4):683-90. PubMed ID: 8616760
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.
    Bachelot T; Bourgier C; Cropet C; Ray-Coquard I; Ferrero JM; Freyer G; Abadie-Lacourtoisie S; Eymard JC; Debled M; Spaëth D; Legouffe E; Allouache D; El Kouri C; Pujade-Lauraine E
    J Clin Oncol; 2012 Aug; 30(22):2718-24. PubMed ID: 22565002
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Effects of high dose raloxifene in selected patients with advanced breast carcinoma.
    Gradishar W; Glusman J; Lu Y; Vogel C; Cohen FJ; Sledge GW
    Cancer; 2000 May; 88(9):2047-53. PubMed ID: 10813716
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.
    Decensi A; Robertson C; Guerrieri-Gonzaga A; Serrano D; Cazzaniga M; Mora S; Gulisano M; Johansson H; Galimberti V; Cassano E; Moroni SM; Formelli F; Lien EA; Pelosi G; Johnson KA; Bonanni B
    J Clin Oncol; 2009 Aug; 27(23):3749-56. PubMed ID: 19597031
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).
    Gershanovich M; Chaudri HA; Campos D; Lurie H; Bonaventura A; Jeffrey M; Buzzi F; Bodrogi I; Ludwig H; Reichardt P; O'Higgins N; Romieu G; Friederich P; Lassus M
    Ann Oncol; 1998 Jun; 9(6):639-45. PubMed ID: 9681078
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Adjuvant tamoxifen for pre- and postmenopausal women with estrogen receptor positive, node positive breast cancer: a randomized study.
    Gundersen S; Hannisdal E; Søreide JA; Skarstein A; Varhaug JE
    Breast Cancer Res Treat; 1995; 36(1):49-53. PubMed ID: 7579506
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Equivalence between ovarian suppression and chemotherapy in the adjuvant treatment of endocrine-responsive breast cancer.
    Di Leo A; Buyse M
    J Clin Oncol; 2002 Apr; 20(7):1954-5. PubMed ID: 11919262
    [No Abstract]   [Full Text] [Related]  

  • 113. Adjuvant therapy for all patients with breast cancer?
    Lippman ME; Hayes DF
    J Natl Cancer Inst; 2001 Jan; 93(2):80-2. PubMed ID: 11208870
    [No Abstract]   [Full Text] [Related]  

  • 114. Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score.
    Sestak I; Cuzick J; Dowsett M; Lopez-Knowles E; Filipits M; Dubsky P; Cowens JW; Ferree S; Schaper C; Fesl C; Gnant M
    J Clin Oncol; 2015 Mar; 33(8):916-22. PubMed ID: 25332252
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Toremifene as a substitute for adjuvant tamoxifen in breast cancer patients.
    Bertelli G; Queirolo P; Vecchio S; Angiolini C; Bergaglio M; Del Mastro L; Signorini A; Valenzano M; Venturini M
    Anticancer Res; 2000; 20(5C):3659-61. PubMed ID: 11268435
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Progesterone receptor quantification as a strong prognostic determinant in postmenopausal breast cancer women under tamoxifen therapy.
    Lamy PJ; Pujol P; Thezenas S; Kramar A; Rouanet P; Guilleux F; Grenier J
    Breast Cancer Res Treat; 2002 Nov; 76(1):65-71. PubMed ID: 12408377
    [TBL] [Abstract][Full Text] [Related]  

  • 117. A randomized phase II trial of aminoglutethimide and hydrocortisone versus combined aminoglutethimide, hydrocortisone and fluoxymesterone in advanced breast cancer.
    Gennatas CS; Kalovidouris A; Paraskevas GA; Kouvaris J; Trichopoulos D; Papavasiliou C
    Radiother Oncol; 1987 Jul; 9(3):217-20. PubMed ID: 3628857
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy.
    Barakat RR; Gilewski TA; Almadrones L; Saigo PE; Venkatraman E; Hudis C; Hoskins WJ
    J Clin Oncol; 2000 Oct; 18(20):3459-63. PubMed ID: 11032585
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Adjuvant hormonal therapy.
    Tamaki Y; Miyoshi Y; Noguchi S
    Breast Cancer; 2002; 9(3):185-9. PubMed ID: 12185327
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Meeting highlights: International consensus panel on the treatment of primary breast cancer.
    Love RR
    J Clin Oncol; 2002 Apr; 20(7):1955-6; author reply 1956-7. PubMed ID: 11919263
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.